# Postoperative Analgesia With Liposomal Bupivacaine Versus Standard Bupivacaine Combined With Dexamethasone

> **NCT06173466** · PHASE4 · COMPLETED · sponsor: **Zhejiang Cancer Hospital** · enrollment: 96 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **DRUG:** Liposomal bupivacaine
- **DRUG:** Bupivacaine Hydrochloride combined with dexamethasone

## Key facts

- **NCT ID:** NCT06173466
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-15
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-05-30
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06173466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06173466, "Postoperative Analgesia With Liposomal Bupivacaine Versus Standard Bupivacaine Combined With Dexamethasone". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06173466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*